TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03739398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))
Description: 1. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASEMED laser(The Thulium laser with 1,927nm wavelength)
Description: 2. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging.
Study: NCT00867789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: 10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
Study: NCT04244526

Intervention type: OTHER
Intervention: Talking a urine sample
Description: Just taking a urine sample

Intervention type: OTHER
Intervention: Talking a urine sample
Description: Just taking a urine sample

Intervention type: OTHER
Intervention: Talking a urine sample
Description: Just taking a urine sample
Study: NCT00549939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight
Study: NCT01389375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemoSeal®
Description: Closure device for femoral artery access closure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExoSeal®
Description: Closure device for femoral artery access closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Conventional manual compression
Study: NCT02946242

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound Exam
Description: Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
Study: NCT02490475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Study: NCT00603460

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DCVax-L and T Cells
Description: Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DCVax-L and T Cells
Description: Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit
Study: NCT02953353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial direct current stimulation (tDCS)
Description: Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hypocaloric diet
Description: During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
Study: NCT01360554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Description: Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator (erlotinib)
Description: Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo erlotinib
Description: placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PF00299804
Description: placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
Study: NCT04341636

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bitewing X ray
Description: Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol .

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bitewing X ray
Description: Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol .
Study: NCT04663789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reinforcement of the staple line
Description: The operator will perform reinforcement of the staple line with a continuous lock stitch.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: staple only
Description: The operator transect the pancreas with stapler only, without staple line reinforcement.
Study: NCT04675164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Assisted Immotile Sperm Selection
Description: LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypo-osmotic Swelling Test
Description: HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
Study: NCT01205230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
Study: NCT01994382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Oral capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion
Study: NCT02509182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% oxygen
Description: An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% oxygen
Description: An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
Study: NCT01312454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-59412C injectable solution
Description: Concentration 1 and Concentration 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-59412C injectable solution
Description: Concentration 1 and Concentration 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost injectable solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-59412C Vehicle
Description: Inactive ingredients used as placebo
Study: NCT04214379

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ptosis surgery
Description: Frontalis sling surgery using pose-up and Wright's fascia-lata needle
Study: NCT03861936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
Study: NCT02833922

Intervention type: BEHAVIORAL
Intervention: Women using Dot to avoid pregnancy
Description: Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
Study: NCT01795885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16 and Pregnant
Description: Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show.
Study: NCT00702364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01710384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Study: NCT01312038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: single 125 mg chewable tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: chewable calcium tablet
Study: NCT03597230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dye
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
Study: NCT03615677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 50mg
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
Study: NCT01349465

Intervention type: DRUG
Group type: OTHER
Intervention: No treatment
Description: No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.

Intervention type: DRUG
Group type: OTHER
Intervention: No treatment
Description: No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
Study: NCT03099642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultrasound-assisted lumbar puncture
Description: The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
Study: NCT02332499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib
Description: Anlotinib p.o. qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study: NCT01612182

Intervention type: OTHER
Intervention: renal replacement therapy
Description: renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )

Intervention type: OTHER
Intervention: renal replacement therapy
Description: renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
Study: NCT00309465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Patients in Group 1 will administer 80% of their usual insulin glargine dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
Study: NCT03270189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prism glasses
Description: orthoptic treatment by wearing prisms when writing
Study: NCT02902354

Intervention type: OTHER
Group type: OTHER
Intervention: Nifedipine for tocolysis
Description: observational
Study: NCT00383084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (LPA)
Description: Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibromyalgia education
Description: Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
Study: NCT01877187

Intervention type: DRUG
Group type: OTHER
Intervention: Lipiodol
Description: Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).